Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.

[1]  H. Meijers-Heijboer,et al.  A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting , 2006, Human mutation.

[2]  J. Klijn,et al.  Survival and prognostic factors in BRCA1-associated breast cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Benítez,et al.  Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Dominique Stoppa-Lyonnet,et al.  Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. , 2005, European journal of cancer.

[5]  H. Nevanlinna,et al.  Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families , 2005, Breast Cancer Research.

[6]  O. Olopade,et al.  The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. , 2005, Gynecologic oncology.

[7]  C. Isaacs,et al.  Utilizing prognostic and predictive factors in breast cancer , 2005, Current treatment options in oncology.

[8]  M. Schutte,et al.  Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant , 2004, Journal of Medical Genetics.

[9]  W. Foulkes,et al.  BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.

[10]  O. Olopade,et al.  Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[11]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[12]  E. Sensi,et al.  p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations , 2003, Breast Cancer Research and Treatment.

[13]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[14]  P. Kyyrönen,et al.  Survival of breast cancer patients in BRCA1, BRCA2, and non‐BRCA1/2 breast cancer families: A relative survival analysis from Finland , 2001, International journal of cancer.

[15]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[16]  E. Berns,et al.  Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  K. Phillips.  Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Å. Borg,et al.  Prognosis and clinical presentation of BRCA2-associated breast cancer. , 2000, European journal of cancer.

[19]  M. Stratton,et al.  The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Andrulis,et al.  Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Nazneen,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[23]  Y. Miki,et al.  Clinicopathologic analysis of BRCA1‐ or BRCA2‐associated hereditary breast carcinoma in Japanese women , 1999, Cancer.

[24]  G. Giles,et al.  The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations , 1998, Cancer.

[25]  D K Gaffney,et al.  Pathobiologic characteristics of hereditary breast cancer. , 1998, Human pathology.

[26]  J. Peto,et al.  Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. , 1998, European journal of cancer.

[27]  M. Stratton,et al.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. , 1998, Journal of the National Cancer Institute.

[28]  Peter Devilee,et al.  BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients , 1997, Nature Genetics.

[29]  P. Tonin,et al.  Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? , 1997, American journal of human genetics.

[30]  J. Klijn,et al.  Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients , 2005, Breast Cancer Research and Treatment.

[31]  B. Agnarsson,et al.  Inherited BRCA2 mutation associated with high grade breast cancer , 2004, Breast Cancer Research and Treatment.

[32]  J. Klijn,et al.  Rapid detection of BRCA1 mutations by the protein truncation test , 1995, Nature Genetics.